Moderna, Inc. (MRNA) Stock: Jefferies Sees $54B Peak Sales for Cancer Therapy
TLDR Moderna shares plunged 24.56% despite positive Phase III melanoma trial results. Jefferies models $54 billion in global peak sales for Moderna’s cancer therapy. The melanoma study met re




